HCB 101
Alternative Names: HCB-101; SIRPα-Fc fusion protein - HanchorBioLatest Information Update: 23 Jun 2025
At a glance
- Originator HanchorBio
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 17 Jun 2025 Interim efficacy data from a phase I trial in Solid tumours released by HanchorBio
- 13 Mar 2025 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT06771622)
- 14 Jan 2025 FBD Biologics plans a phase I/II trial for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in January 2025 (NCT06771622)